This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets. Changes to authorisations most relevant to vets The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed. Chang

The Equine Quarterly Disease Surveillance Report Q3 2024 produced by Equine Infectious Disease Surveillance, is now available. Some of the key updates included in the report are: NEWS: The Equine Industries Committee - Who, what, and why? NEWS: Strategies to monitor and combat parasite-related disease and anthelmintic resistance in horses FOCUS: An ongoing concern: Twenty years of research on equine atypical myopathy with a focus on UK surveillance data You will also be able to find EIDS’

The BEVA Sustainability Working Group have been developing guidelines on the use of equine endo- and ecto-parasite treatments, focusing on minimising their environmental impact. These expand on a number of recently published articles, including the CANTER guidelines for sustainable equine parasite control. The BEVA Guidelines will take the form of guidance for vets, a helpsheet for clients, and a number of additional resources. For more information in the meantime, take a look at the following: